Inventor · disambiguated record
Laurent Audoly
Also filed as: AUDOLY LAURENT · AUDOLY LAURENT P · AUDOLY LAURENT PASCAL
12 granted patents·10 pending applications·43 citations·filing 2002–2023
90Inventor score
Files withPIERIS PHARMACEUTICALS GMBH14PFIZER3UNIV VANDERBILT2HORRIGAN STEPHEN K1INCENDIATHERAPEUTICS INC1
Top patents by PatentIndex Score
22 records- 0193US10857202B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Dec 8, 2020·4 cites·18 claims
- 0292US11382951B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Jul 12, 2022·2 cites·19 claims
- 0392US10526382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 7, 2020·6 cites·47 claims
- 0490US10016483B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 10, 2018·6 cites·20 claims
- 0587US10526384B2Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2013·Granted Jan 7, 2020·5 cites·16 claims
- 0687US10398754B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Sep 3, 2019·4 cites·19 claims
- 0783US9572863B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Feb 21, 2017·4 cites·20 claims
- 0882US9950034B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Apr 24, 2018·3 cites·20 claims
- 0982US9610356B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Apr 4, 2017·7 cites·23 claims
- 1079US2023021168A1Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 1175US12014835B2Methods for evaluating therapeutic benefit of combination therapiesUNIV VANDERBILT·Filed 2021·Granted Jun 18, 2024·1 cites·20 claims
- 1263US11034738B2Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·18 claims
- 1362US10064963B2Methods and compositions for treating disordersPIERIS AG·Filed 2013·Granted Sep 4, 2018·1 cites·8 claims
- 1460US2020148733A1Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 1556US2017066807A1Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3PIERIS PHARMACEUTICALS GMBH·Filed 2016·Application pending·0 cites
- 1655US2018311311A1Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 1751US2025369982A1Methods of detecting ddr1 phosphorylationINCENDIATHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1848US2023084515A1Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapyUNIV VANDERBILT·Filed 2021·Application pending·0 cites
- 1946US2010093611A1Compounds and methods for treating or preventing autoimmune diseasesHORRIGAN STEPHEN K·Filed 2008·Application pending·0 cites
- 2041US2009036495A1Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor AntagonistsPFIZER·Filed 2005·Application pending·0 cites
- 2141US2003131370A1Disruption of the glutathione S-transferase-Omega-1 genePFIZER·Filed 2002·Application pending·0 cites
- 2235US2003106085A1Disruption of the prostaglandin E synthase 2 genePFIZER·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laurent Audoly files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →